Stoke Therapeutics, Inc. - Common Stock (STOK)
CUSIP: 86150R107
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 57,529,259
- Total 13F shares
- 9,494
- Share change
- +4,500
- Total reported value
- $309,103
- Price per share
- $32.56
- Number of holders
- 5
- Value change
- +$146,508
- Number of buys
- 4
Quarterly Holders Quick Answers
What is CUSIP 86150R107?
CUSIP 86150R107 identifies STOK - Stoke Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 86150R107:
Top shareholders of STOK - Stoke Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
9.8%
from 13D/G
|
5,600,920
|
$177,773,201 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
10%
from 13D/G
|
5,546,856
|
$176,057,209 | — | 31 Dec 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
9.4%
|
5,404,674
|
$171,544,353 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.8%
from 13D/G
|
5,212,554
|
$165,446,463 | — | 31 Dec 2025 | |
| Redmile Group, LLC |
13F
13D/G
|
Company |
8%
from 13D/G
|
4,034,070
|
$128,041,382 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
6.5%
from 13D/G
|
3,546,158
|
$112,555,054 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
13D/G
|
Company |
5.8%
from 13D/G
|
3,336,697
|
$105,906,763 | — | 31 Dec 2025 | |
| TORONTO DOMINION BANK |
13F
13D/G
|
Company · The Toronto-Dominion Bank |
5.8%
from 13D/G
|
3,173,258
|
$100,719,209 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.5%
|
3,149,239
|
$99,956,846 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
4.3%
|
2,498,049
|
$79,288,075 | — | 31 Dec 2025 | |
| BVF INC/IL |
13F
|
Company |
3.9%
|
2,265,674
|
$71,912,493 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.9%
|
2,247,347
|
$71,330,794 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
3.2%
|
1,823,500
|
$57,877,890 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.5%
|
1,450,933
|
$46,031,447 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
2.2%
|
1,269,131
|
$40,282,218 | — | 31 Dec 2025 | |
| Skorpios Trust |
3/4/5
13D/G
|
10%+ Owner · Montrago Trustees Ltd |
4.1%
from 13D/G
|
3,906,181
|
$39,843,046 | -$30,600,000 | 04 Jun 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
2.1%
|
1,227,723
|
$38,967,928 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.1%
|
1,222,213
|
$38,793,041 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
1,166,145
|
$37,019,868 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
1,142,737
|
$36,270,472 | — | 31 Dec 2025 | |
| BlackRock Portfolio Management LLC |
13D/G
|
— |
4.7%
|
2,550,341
|
$28,946,115 | -$2,192,358 | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.4%
|
827,139
|
$26,253,770 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.3%
|
770,289
|
$24,448,973 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.3%
|
735,799
|
$23,354,261 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
1.2%
|
695,000
|
$22,059,300 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.87%
|
500,000
|
$15,870,000 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.78%
|
446,690
|
$14,178,544 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.75%
|
430,155
|
$13,653,120 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.71%
|
410,906
|
$13,042,156 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.7%
|
403,168
|
$12,796,553 | — | 31 Dec 2025 | |
| Erste Asset Management GmbH |
13F
|
Company |
0.69%
|
396,000
|
$12,598,080 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.65%
|
372,334
|
$11,818,000 | — | 31 Dec 2025 | |
| Adrian R. Krainer |
3/4/5
|
Director |
—
mixed-class rows
|
313,049
mixed-class rows
|
$11,257,458 | -$3,902,456 | 10 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.48%
|
277,930
|
$8,821,499 | — | 31 Dec 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.45%
|
260,000
|
$8,252,400 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.45%
|
259,543
|
$8,237,895 | — | 31 Dec 2025 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
0.43%
|
246,900
|
$7,836,606 | — | 31 Dec 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.38%
|
216,000
|
$6,855,840 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.36%
|
206,164
|
$6,543,645 | — | 31 Dec 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.33%
|
191,397
|
$6,074,941 | — | 31 Dec 2025 | |
| Edward M. Kaye MD |
3/4/5
|
Director |
—
mixed-class rows
|
743,675
mixed-class rows
|
$5,449,282 | -$4,246,943 | 15 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.3%
|
169,713
|
$5,386,690 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.28%
|
162,679
|
$5,163,431 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.26%
|
150,945
|
$4,790,994 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
140,802
|
$4,469,056 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.23%
|
132,222
|
$4,196,726 | — | 31 Dec 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.22%
|
126,350
|
$4,010,349 | — | 31 Dec 2025 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.21%
|
122,448
|
$3,886,500 | — | 31 Dec 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.2%
|
117,823
|
$3,739,702 | — | 31 Dec 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.2%
|
115,539
|
$3,667,208 | — | 31 Dec 2025 |
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock (STOK) as of Q1 2026
As of 31 Mar 2026,
Stoke Therapeutics, Inc. - Common Stock (STOK) was held by
5 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,494 shares.
The largest 5 holders included
Generali Investments, Management Co LLC, Versant Capital Management, Inc, GAMMA Investing LLC, SIGNATUREFD, LLC, and Farther Finance Advisors, LLC.
This page lists
5
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
181
Q1 2026 holders
5
Holder diff
-176
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.